摘要
异烟肼(INH)和利福平(RFP)是临床抗结核一线药物,也是我国急性药物性肝损伤(DILI)的重要病因。INH和RFP单独使用均会引起DILI,二者联用会使肝损伤的发生率及严重程度显著增加。目前临床上对INH、RFP致肝损伤的检测指标主要有血清转氨酶、总胆红素等,存在灵敏度和特异性不高、早期预测性差等缺点。近年来多项研究试图通过多种方法发现更为理想的生物标志物,提高对INH、RFP致DILI检测与诊断的特异性与灵敏性。本文从代谢组学、蛋白质组学、转录组学、基因组学等方面就INH、RFP致DILI的新型潜在生物标志物予以综述。
Isoniazid(INH)and rifampicin(RFP)are the first-line clinical anti-tuberculosis drugs and also the important cause of acute drug induced liver injury(DILI)in China.Each of isoniazid and rifampin can cause liver injury,and the combination of the two will increase the incidence and severity of liver damage significantly.At present,biomarkers of INH and RFP induced liver damage like serum transaminases and bilirubin,etc.,which have the defects of low sensitivity and specificity and poor early predictability.In recent years,many studies have tried to find more ideal biomarkers to improve the specificity and sensitivity of the detection and diagnosis of drug induced liver injury.In this paper,we have reviewed the new potential biomarkers related to isoniazid and rifampin discovered in recent years from the aspects of metabolomics,proteomics,transcriptomics and genomics.
作者
朱家莲
龚奕
彭文兴
ZHU Jia-lian;GONG Yi;PENG Wen-xing(Department of Pharmacy, Second Xiangya Hospital, Central South University, Hunan Changsha 410011, China;Institute of Clinical Pharmacy, Central South University, Hunan Changsha 410011, China)
出处
《中国医院药学杂志》
CAS
北大核心
2018年第22期2380-2383,共4页
Chinese Journal of Hospital Pharmacy
